Literature DB >> 27003664

Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease.

Jody Corey-Bloom1, Shea Gluhm1, Andrew Herndon1, Ameera S Haque1, Sungmee Park1, Paul E Gilbert2.   

Abstract

BACKGROUND: Visuospatial deficits have been described in Huntington's disease (HD); however, the extent of these deficits remains unclear. The Benton Judgment of Line Orientation (JoLO) Test, commonly used to assess visuospatial ability, requires minimal motor involvement. It has demonstrated sensitivity to visuospatial deficits in Parkinson's disease; however, few studies have examined performance on this test in HD.
OBJECTIVE: The objective of the current study was to assess visuospatial ability in premanifest and manifest HD using the JoLO.
METHODS: A global cognitive measure, the Mattis Dementia Rating Scale (DRS), was used to stratify manifest HD patients as mild (DRS ≥129) vs. moderate-severe (DRS ≤128). Fifty mild, 42 moderate-severe, and 30 premanifest HD subjects, as well as 35 matched controls, were administered the JoLO. HD Burden of Pathology (BOP) scores were used as a measure of disease severity.
RESULTS: Results revealed that the total manifest HD sample (p <  0.001), in addition to the mild (p = 0.028), and moderate-severe (p <  0.001), but not premanifest, HD subjects scored significantly lower on the JoLO compared to normal controls.
CONCLUSIONS: Our results suggest that the JoLO is useful for detecting visuospatial deficits across various stages of manifest HD. However, any visuospatial impairment that might be present during the premanifest stage of HD was not detected using the JoLO in the present sample.

Entities:  

Keywords:  Huntington’s disease; Judgment of Line Orientation (JoLO); visuospatial impairment

Mesh:

Year:  2016        PMID: 27003664     DOI: 10.3233/JHD-150175

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  4 in total

Review 1.  What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.

Authors:  Lukasz Przybyl; Magdalena Wozna-Wysocka; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

2.  Effect of Trinucleotide Repeats in the Huntington's Gene on Intelligence.

Authors:  Jessica K Lee; Amy Conrad; Eric Epping; Kathy Mathews; Vincent Magnotta; Jeffrey D Dawson; Peg Nopoulos
Journal:  EBioMedicine       Date:  2018-03-30       Impact factor: 8.143

3.  Impaired Performance of the Q175 Mouse Model of Huntington's Disease in the Touch Screen Paired Associates Learning Task.

Authors:  Tuukka O Piiponniemi; Teija Parkkari; Taneli Heikkinen; Jukka Puoliväli; Larry C Park; Roger Cachope; Maksym V Kopanitsa
Journal:  Front Behav Neurosci       Date:  2018-10-02       Impact factor: 3.558

Review 4.  Prediction of cognitive dysfunction after resuscitation - a systematic review.

Authors:  Wioletta A Mędrzycka-Dąbrowska; Katarzyna Czyż-Szybenbejl; Katarzyna Kwiecień-Jaguś; Katarzyna Lewandowska
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-09-21       Impact factor: 1.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.